zurück

Pembrolizumab (new indication: melanoma, patients aged ≥ 12 to 18 years)

 

Subject:

  • Active Sustance: Pembrolizumab
  • Name: Keytruda®
  • Therapeutic area: Melanoma
  • Pharmaceutical company: MSD Sharp & Dohme GmbH

 

Time table:

  • Start: 01.08.2022
  • Publication of assessment: 01.11.2022
  • End of public hearing: 22.11.2022
  • Final decision by G-BA: middle of January 2023

 

Comparative therapy:

  • Therapy at the physician's discretion, appropriate therapies include:
    • vemurafenib + cobimetinib (for patients with BRAF V600 mutation only) OR
    • dabrafenib + tramentinib (for patients with BRAF V600 mutation only) OR
    • encorafenib + binimetinib (for patients with BRFAF V600 mutation only) OR
    • nivolumab